Janus Henderson Group PLC Purchases 21,793 Shares of Bruker Co. (NASDAQ:BRKR)

Janus Henderson Group PLC grew its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 890,189 shares of the medical research company's stock after buying an additional 21,793 shares during the quarter. Janus Henderson Group PLC owned 0.59% of Bruker worth $61,480,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Tidal Investments LLC bought a new position in Bruker during the first quarter worth about $218,000. Cetera Investment Advisers grew its position in shares of Bruker by 350.0% during the 1st quarter. Cetera Investment Advisers now owns 33,131 shares of the medical research company's stock worth $3,112,000 after purchasing an additional 25,768 shares in the last quarter. Cetera Advisors LLC acquired a new position in Bruker during the first quarter valued at approximately $693,000. CWM LLC lifted its stake in shares of Bruker by 165.4% in the 2nd quarter. CWM LLC now owns 4,777 shares of the medical research company's stock valued at $305,000 after acquiring an additional 2,977 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Bruker by 2,125.7% in the second quarter. SG Americas Securities LLC now owns 27,465 shares of the medical research company's stock worth $1,753,000 after purchasing an additional 26,231 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. TD Cowen decreased their price target on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research note on Wednesday, November 6th. Citigroup dropped their price objective on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group upgraded shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price for the company in a research report on Thursday. Barclays cut their price objective on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Finally, Wolfe Research lowered Bruker from an "outperform" rating to a "peer perform" rating in a research note on Monday, September 30th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $79.36.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the transaction, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 28.30% of the company's stock.

Bruker Price Performance

BRKR stock traded up $0.48 on Friday, reaching $58.96. The company had a trading volume of 1,094,026 shares, compared to its average volume of 1,114,777. The company has a market cap of $8.94 billion, a P/E ratio of 28.35, a PEG ratio of 3.86 and a beta of 1.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86. The company's fifty day moving average is $59.84 and its 200 day moving average is $63.60.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company's revenue for the quarter was up 16.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.74 earnings per share. On average, research analysts forecast that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. Bruker's dividend payout ratio is currently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.